Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Canada to Develop New Isotope Production Methods

By BiotechDaily International staff writers
Posted on 11 Mar 2013
Print article
An aging reactor and a worldwide looming shortage of medical isotopes has driven Canada to search for alternatives methods to manufacture technetium-99m (99mTc).

At the moment, Canada's only source of the isotope is the National Research Universal (NRU; Chalk River, Ontario, Canada) reactor at Chalk River Laboratories (CRL, Ontario, Canada), which produces about a third of the world's supply. But the reactor has been plagued with safety and operational problems, leading to worldwide shortages, and its license is set to expire in 2016. Consequently, Canada is investing close to USD 21 million in three projects in western Canada that have demonstrated the ability to produce the key medical isotope without a nuclear reactor.

Two of the research institutes, the national laboratory for particle and nuclear physics (TRIUMF; Vancouver, BC, Canada) and the University of Alberta (Edmonton, Canada) are using cyclotron technology to produce the isotope, while the third, Prairie Isotope Production Enterprise (PIPE; Pinawa, MB, Canada), is using a linear accelerator.

In the cyclotron process, the machine bombards a target of molybdenum-100 with high-energy protons, converting some of its atoms to molybdenum-99 (Mo-99). Then chemical processing removes technetium-99 from the target, ready for use. The PIPE technology uses an electron accelerator rather than a nuclear reactor to make the Mo-99. The electron accelerator sprays electricity onto molybdenum metal, which produces the Mo-99 radioisotope. Next, a chemical process is used to fabricate the Tc-99m.

“The Harper Government is investing in Canadian expertise to help ensure new sources of supply for medical isotopes used in diagnosing various diseases, such as cancer and heart disease,” said Joe Oliver Canada’s natural resources minister. “We are investing in the work needed to attract private sector interest and to bring new technologies to market, and to help ensure that isotope production is on a sound commercial footing.”

Tc-99m is obtained from the decay of its parent isotope Mo-99 compounds that are packed into nuclear "generators" and distributed to hospitals, where nuclear medicine specialists can draw off the Tc-99m as needed for about a week. Tc-99m is used in 80% of nuclear medicine diagnostic procedures in Canada, and about 85% of all medical imaging procedures worldwide. It is currently made in reactors in Canada, the Netherlands, Belgium, France, Australia, and South Africa.

Related Links:

National Research Universal
TRIUMF
Prairie Isotope Production Enterprise



Print article

Channels

Genomics/Proteomics

view channel
Image: Healthy blood cells along with sickle-cell diseased cells (Photo courtesy of Science Picture Co./Corbis).

Gene Editing Corrects Hemoglobin Defects in Beta-Thalassemia and Sickle Cell Disease

A team of hematology researchers used the CRISPR/Cas9 gene editing technique to correct the mutations that cause defective blood cell morphology in beta-thalassemia and sickle cell disease.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.